- Home
- TRUG vs TSBX Comparison
TRUG vs TSBX Comparison
Compare TRUG & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUG
- TSBX
- Stock Information
- Founded
- TRUG 1983
- TSBX 2015
- Country
- TRUG United States
- TSBX United States
- Employees
- TRUG N/A
- TSBX N/A
- Industry
- TRUG
- TSBX
- Sector
- TRUG
- TSBX
- Exchange
- TRUG NYSE
- TSBX Nasdaq
- Market Cap
- TRUG 13.7M
- TSBX 11.8M
- IPO Year
- TRUG N/A
- TSBX 2023
- Fundamental
- Price
- TRUG $0.95
- TSBX $0.45
- Analyst Decision
- TRUG
- TSBX Strong Buy
- Analyst Count
- TRUG 0
- TSBX 2
- Target Price
- TRUG N/A
- TSBX $6.88
- AVG Volume (30 Days)
- TRUG 11.3K
- TSBX 145.4K
- Earning Date
- TRUG 10-15-2024
- TSBX 11-07-2024
- Dividend Yield
- TRUG N/A
- TSBX N/A
- EPS Growth
- TRUG N/A
- TSBX N/A
- EPS
- TRUG N/A
- TSBX N/A
- Revenue
- TRUG $19,112,071.00
- TSBX N/A
- Revenue This Year
- TRUG N/A
- TSBX N/A
- Revenue Next Year
- TRUG N/A
- TSBX N/A
- P/E Ratio
- TRUG N/A
- TSBX N/A
- Revenue Growth
- TRUG N/A
- TSBX N/A
- 52 Week Low
- TRUG $0.79
- TSBX $0.45
- 52 Week High
- TRUG $11.82
- TSBX $5.75
- Technical
- Relative Strength Index (RSI)
- TRUG 41.33
- TSBX 16.75
- Support Level
- TRUG $0.79
- TSBX $0.58
- Resistance Level
- TRUG $1.03
- TSBX $0.70
- Average True Range (ATR)
- TRUG 0.11
- TSBX 0.05
- MACD
- TRUG -0.01
- TSBX 0.03
- Stochastic Oscillator
- TRUG 34.98
- TSBX 1.10
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games ("Links"), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.
About TSBX Turnstone Biologics Corp.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.